Evaluation of the Hepatitis C Care Cascade in the Country of Georgia: Monitoring Progress towards Elimination- T. Tsertsvadze

International Viral Hepatitis Elimination Meeting (IVHEM) 2019

Strategies towards Elimination of Hepatitis C in Iceland: Models of Care for the Treatment as Prevention for Hepatitis C (TraP HeP C) Program- M. Gottfredsson

International Viral Hepatitis Elimination Meeting (IVHEM) 2019

Micro-Elimination of Hepatitis C amongst People Living with HIV (PLHIV) in Punjab, India- P. Katapur

International Viral Hepatitis Elimination Meeting (IVHEM) 2019

Integration of Hepatitis C Treatment Services with Harm Reduction Service Centers for People who Inject Drugs in Kenya: Experience from Test and Link to Care for Injecting Drug Users Study- M. Nyakowa

International Viral Hepatitis Elimination Meeting (IVHEM) 2019

Towards the Elimination of HCV in British Columbia: A strategy to Address the “messy middle”- B. Conway

International Viral Hepatitis Elimination Meeting (IVHEM) 2019

Real-World Challenges to and Opportunities for Microelimination in Two Remote Communities in Northwestern Ontario- D. Smookler

International Viral Hepatitis Elimination Meeting (IVHEM) 2019

Policy Implementation Index Based off of Patient Reported Outcomes: The Hep-CORE Study- A. Palayew

International Viral Hepatitis Elimination Meeting (IVHEM) 2019

Mongolia’s Model for Care- Naranjargal Dashdorj, MD, PhD

International Viral Hepatitis Elimination Meeting (IVHEM) 2019

Hepatitis C Elimination in the Netherlands (CELINE): a Nationwide Study Retrieving Lost to Follow-Up Chronic Hepatitis C Patients- M. Van Dijk

International Viral Hepatitis Elimination Meeting (IVHEM) 2019

Oral Prescription Opioid Use should be Considered a Risk Factor for HCV Infection: Another Step Toward HCV Elimination- B. Hack

International Viral Hepatitis Elimination Meeting (IVHEM) 2019

New Designs for Early Clinical Trials of IO Drugs - Emiliano Calvo, Md, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Changes and Challenges in Early Phase Trial Endpoints - Ruth Plummer, MD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Long Term Pemetrexed-based Cancer Treatment Leads to Nephrotoxicity - Nikki de Rouw

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Prediction of Capecitabine induced Severe Toxicity using Machine Learning Techniques - Maël Steunou

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

The Long and Winding Road of the Clinical Introduction of a Biomarker - Jack Schalken, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

The Use of Radiolabeled and Fluorescent Monoclonal Antibodies for Molecular Imaging in Oncology - Annelies Jorritsma-Smit, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Epigenetic Regulation of OCTN1-mediated Cytarabine Transport in Acute Myeloid Leukemia - Jason Anderson

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Comprehensive Pan-Cancer Analysis of Somatic Mutations in Drug Transporters to Reveal Acquired and Intrinsic Drug Resistance in 3149 Metastatic Cancer Patients - Wesley van de Geer

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

How System Pharmacology Can Facilitate Clinical Drug Development in Oncology - Piet van der Graaf, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Impact of Immortal Time and Selection Bias on Exposure-response Modelling - Mats Karlsson, PhD, FCP, FISoP

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Clinical Pharmacology Strategy for Development and Labelling of New Medicine in the Era of Targeted Therapy and Accelerated Approvals in Oncology - Berges & Schalkwijk

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Population Pharmacodynamics Modelling of Circulating Lymphocyte Count Over Time in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment - Fanny Gallais

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Challenges in the Development of Immunotherapy - Candice Jamois, PharmD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Optimal Study Design of Oncology Trials - Patricia LoRusso, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019